[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cystoscopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cystoscopy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,76,106,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100638845","phase-4-comparison-of-hemodynamic-stability-with-075percent-and-05percent-hyperbaric-bupivacaine-during-spinal-anesthesia-in-cystoscopic-procedures-100638845",false,"NCT07590544","Comparison of Hemodynamic Stability With 0.75percent and 0.5percent Hyperbaric Bupivacaine During Spinal Anesthesia in Cystoscopic Procedures","Comparison of Hemodynamic Stability With 0.75 vs 0.5percent Hyperbaric Bupivacaine During Spinal Anesthesia in Cystoscopic Procedures:A Randomized Control Trial","Inclusion Criteria:\n\n* Patients aged 18-80 years. American society of Anesthesiologist(ASA) physical status I-II. Sceduled for elective cystoscopic procedures under spinal anesthesia.\n\nExclusion Criteria:\n\n* Patient refusal. Contraindication to spinal anesthesia(e.g coagulopathy ,infection at injection site).\n\nKnown hypersensitivity to bupivacaine. Significant cardiovascular,hepatic or renal disease.","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Purpose:The aim of this study is to determine the intrathecal Bupivacaine concentration(0.5% vs 0.75%) with better anesthesia and little hemodynamic disturbance during cystoscopic procedures.In comparing these bupivacaine concentrations ,the result would be expected to enhance safer spinal anesthesia practices ,minimizing the use of vasopressors in urological surgeries.OBJECTIVE:To compare and analyze the frequency and average chages of post spinal hemodynamic instability in terms of hypotension and bradycardia with 0.75% hyperbaric bupivacaine and 0.55 hyperbaric bupivacaine in patients presenting for cystoscopic procedures.",[27],"Cystoscopy",[29,30,31,32],"spinal anesthesia","hyperbaric bupivacaine","cystoscopy","hemodynamic stability","NOT_YET_RECRUITING","2026-05-10",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":21},"2026-07",{"date":41,"type":21},"2026-12",{"name":43,"class":44},"PAEC General Hospital, Islamabad","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100606796","guiding-value-of-urinary-tumor-dna-testing-in-cystoscopy-for-high-riskvery-high-risk-non-muscle-invasive-bladder-cancer-100606796","NCT07180212","Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk\u002FVery High-Risk Non-Muscle-Invasive Bladder Cancer","The Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk\u002FVery High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multicenter Clinical Study (Truce-LB02)","Inclusion Criteria:\n\n1. Male or female participants aged 18 years or older.\n2. Histologically confirmed high-risk or very high-risk non-muscle-invasive urothelial carcinoma (NMIBC) of the bladder, as defined by the EAU 2025 NMIBC guidelines, or bladder tumors in which high-risk\u002Fvery high-risk NMIBC constitutes more than 50% of the pathological composition, diagnosed within the past 2 years, with no evidence of muscle-invasive bladder cancer or metastatic disease.\n3. Prior to enrollment, participants must have undergone either:\n\nA.Second transurethral resection of bladder tumor (re-TURBT), or B.Complete initial TURBT with negative basal margins, peripheral margins, and multiple site biopsies, with pathological specimens including detrusor muscle and showing no residual tumor, and negative urine cytology at 2 weeks post-surgery.\n\nExclusion Criteria:\n\n1.History of upper urinary tract malignancy (ureter or renal pelvis) within the past 5 years or concurrent diagnosis of upper urinary tract urothelial carcinoma.",{"count":54,"type":21},360,[56],"NA","Non-muscle-invasive bladder cancer (NMIBC) is usually treated with surgery to remove the tumor (transurethral resection of bladder tumor, or TURBT), often followed by bladder-instilled medications to reduce the chance of the cancer coming back. Even with this treatment, high-grade NMIBC can return or progress, so patients need regular check-ups, usually with cystoscopy (a camera examination of the bladder) and urine cytology.\n\nCystoscopy is effective but invasive, can cause discomfort, and carries risks such as infection and bleeding. This makes follow-up costly and sometimes burdensome for patients.\n\nThis study is testing whether a urine tumor DNA (utDNA) test - a type of \"liquid biopsy\" that detects cancer-related DNA changes in urine - can help guide the timing of cystoscopy for people with high-risk or very high-risk NMIBC. utDNA testing is non-invasive and has shown high accuracy in detecting bladder cancer, sometimes spotting signs of recurrence earlier than standard methods.\n\nBy combining utDNA testing with cystoscopy, we hope to safely reduce the number of unnecessary cystoscopies without missing cancer recurrences. The study will evaluate whether this approach can make bladder cancer follow-up more comfortable, more precise, and more efficient.",[59,60,27],"Bladder Cancer","Liquid Biopsy",[62,63,31,64],"bladder cancer","liquid biopsy","urine tumor DNA","RECRUITING","2026-05-06",{"date":68,"type":37},"2026-05-11",{"date":70,"type":37},"2025-09-20",{"date":72,"type":21},"2027-11-01",{"name":74,"class":44},"Tianjin Medical University Second Hospital",8,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":5},"100578964","bladder-epicheck-european-haematuria-study-100578964","NCT06818136","Bladder EpiCheck European Haematuria Study","Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria","Inclusion Criteria:\n\n1. Participants aged 45 years or older\n2. Participants who are willing and able to provide written informed consent and adhere to study procedures\n3. Participants presenting with visible and\u002For non-visible haematuria within 6 months prior to study enrollment\n4. Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment\n5. Participants who are able to produce at least 10 ml of voided urine\n\nExclusion Criteria:\n\n1. Participants with history of urothelial cancer in the bladder and\u002For upper urinary tract\n2. Participants who had prior cystoscopy for haematuria within the past 2 years\n3. Participants previously enrolled in this study\n4. Participants treated for prostate cancer within the last 12 months\n5. Participants treated for kidney cancer within the last 12 months\n6. Participants with untreated urinary tract infection\n7. Participants with symptomatic urinary tract stones (e.g. flank pain)\n8. Participants on dialysis for end stage renal failure\n9. Participants with a long term urinary catheter\n10. Pregnancy (self-reported)\n11. Participants who, because of medical status, or frailty is not expected to be able to complete the full diagnostic pathway","45 Years",{"count":85,"type":21},800,"OBSERVATIONAL","The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.\n\nParticipants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.",[89,27,90,91,92],"Hematuria","Urothelial Carcinoma Bladder","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma of the Urinary Bladder",[94,95,96],"urine test","methylation","primary detection","2026-01-21",{"date":99,"type":37},"2026-01-22",{"date":101,"type":37},"2025-06-20",{"date":41,"type":21},{"name":104,"class":105},"Nucleix Ltd.","INDUSTRY",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100573852","xpert-bladder-monitor-a-non-invasive-follow-up-tool-for-detecting-relapse-in-high-grade-or-high-risk-bladder-cancer-100573852","NCT06751667","Xpert Bladder Monitor: a Non-Invasive Follow-Up Tool for Detecting Relapse in High Grade or High Risk Bladder Cancer","LIBERO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf\n* NMIBC high grade or high risk (already subjected to or currently undergoing treatment with BCG).\n* No contraindications to surgery\n\nExclusion Criteria:\n\n* Inability or unwillingness of the participant or their legal representative to provide written informed consent\n* Absolute contraindications to surgery or cystoscopy\n* Patients who have previously participated in clinical protocols involving chemotherapy drugs or immunotherapy\n* Patients with multiple recurrent tumors eligible for cystectomy or Muscle-Invasive Bladder Cancer (MIBC)",{"count":114,"type":21},50,[56],"Main objectives:\n\nQualitative and quantitative monitoring of recurrences in patients with a previous diagnosis of high-grade bladder cancer at high risk of persistence\u002Frecurrence.\n\nEndpoints: Presence or absence of mRNA in urine with a dichotomous result; concordance between Xpert BM and histopathological examination\n\nClinical relevance: reduces by half the number of (invasive) cystoscopies during follow-up. The non-invasive nature of the test could improve patient compliance with follow-up. Interventional study because it would reduce by half the number of cystoscopies during follow-up of bladder cancer which is considered the gold standard in the follow-up of this tumor. However, these markers are already CE validated and described in the European guidelines and for this reason the risk would be low.",[118,59,119,120,27],"Bladder (Urothelial, Transitional Cell) Cancer","Bladder Tumors","Bladder Cancer Recurrence",[122,123],"Xpert Bladder Monitor","Gene Xpert","2024-12-20",{"date":126,"type":37},"2024-12-30",{"date":128,"type":21},"2025-01-01",{"date":130,"type":21},"2032-01-01",{"name":132,"class":44},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":45},"100471189","augmented-bladder-tumor-detection-using-real-time-based-artificial-intelligence-100471189","NCT05415631","Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence","Augmented Bladder Tumor Detection Using the Bladder-Portable Artifact Detection System: A Multicentric Prospective Analytic Study Using Real Time Based Artificial Intelligence (IA).","Bladder-PAD","Inclusion Criteria:\n\n* unifocal primary or recurrent suspected bladder cancer with tumor size less or equal than 3 cm\n* multifocal primary or recurrent suspected bladder cancer less or equal than 5 lesions and with tumor size less or equal than 3 cm.\n\nExclusion Criteria:\n\n* Evidence of more than 5 tumors or more than 3 cm\n* computed tomography\u002Fcystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)\n* computed tomography\u002Fmagnetic resonance evidence of distant metastases (lymphatic or organic)\n* Exclusion criteria will include gross hematuria and bacillus Calmette-Guerin (BCG) treatment or chemotherapy within 3 months of inclusion\n* An exception will be made if patients had received only a single course of chemotherapy immediately following TUR\n* Patients objecting to the use of their data in the context of research.",{"count":142,"type":21},500,"Today the standard for the diagnosis and monitoring of bladder tumors is bladder endoscopy. The performance of this exam is not perfect. With this work, based on artificial intelligence, the investigators wish to combine endoscopy with a complementary diagnostic tool in order to improve patient care. The main objective will be to reduce diagnostic errors \u002F wanderings in patients treated or followed for bladder tumors, by imposing a new standard of diagnostic bladder mapping (high PPV and VPN, high precision)(primary purpose diagnostic). The secondary objective will be to homogenize and systematize the descriptive part of the lesions, and to use AI to better characterize tumor aggressiveness. The final objective being to validate a new precision tool (diagnostic companion) essential for developing and standardizing the therapeutic management of bladder tumors (correcting inter-observer heterogeneity).\n\nIn this project, video frame will be first extracted from our dataset of cystoscopy videos hosted in in the Next Cloud Recherche. Selected medical image will be segmented and analyzed using our pre-trained CNN model with a feature detection algorithm to obtain features.\n\nData will be analyzed on both patient and lesion levels. The study will assess the Bladder-PAD accuracy on the detection of bladder tumors, and its ability to predict tumor risk of recurrence and progression.",[59,27,145],"Artificial Intelligence",[59,31,145],"2022-07-13",{"date":149,"type":37},"2022-07-15",{"date":151,"type":37},"2022-05-13",{"date":153,"type":21},"2029-05",{"name":155,"class":44},"Centre Hospitalier Universitaire, Amiens"]